Sunitinib Malate Market

Sunitinib Malate Market Forecast for Pancreatic Cancer, 2016-2017, G7 Countries, (U.S., Germany, France, U.K., Italy, Spain, Japan)

Report Code: PH 4322 May, 2016, by marketsandmarkets.com

The sunitinib malate market for pancreatic cancer is projected to reach USD 76.7 Million by 2021, at a CAGR of 13.9% from 2016 to 2021.

Over the years, the sunitinib malate market for pancreatic cancer has observed steady growth and this trend is expected to continue in the coming years. This is primarily because the market is witnessing increasing adoption of drug therapy for the treatment of pancreatic cancer. This report categorizes patients with pancreatic neuroendocrine tumors (pNET) based on three different stages, namely, localized, advanced, and distant. The number of patients suffering from distant pNET is higher as this type of tumor causes practically no symptoms, owing to which it is difficult to diagnose it in early stages.

The U.S. is the largest market for sunitinib malate for the treatment of pancreatic cancer, followed by Japan and Germany. Growth in the U.S. market is primarily driven by the higher incidence of pancreatic cancer and the growing adoption of sunitinib malate for pNET treatment.

A number of factors, such as the growing number of pancreatic cancer patients, poor diagnosis rates in early stages of pancreatic cancer, and availability of a limited number of drug therapy options for the treatment of advanced pNET are driving the demand of sunitinib malate in the treatment of pancreatic cancer. Also, the overall number of patients who are eligible for taking sunitinib malate is expected to increase at a CAGR of more than 4% in G7 countries during the forecast period.

The market sizing and forecasting of sunitinib malate for pancreatic cancer was done in four steps. In the first step, the number of patient and their growth rate was identified based on epidemiology studies. The incidence and five-year survival of patients suffering from pNET cancer was considered. In the second step, treatment options were identified based on stage and type of tumor. Through this, the number of patients eligible for sunitinib malate was estimated. In the third step, the annual cost of therapy was estimated based on dosage regimen and price of products. In the final step, the market size of sunitinib malate for pancreatic cancer was estimated based on the number of patients eligible for sunitinib malate, annual cost of therapy, and inflation rate.

Target Audience

  • Pharmaceutical Companies
  • CROs
  • Hospitals
  • Oncology Centers
  • Health Insurance Payers
  • Regulatory Authorities
  • Medical Oncologists
  • Oncology Registries

To know about the assumptions considered for the study, download the pdf brochure

Scope of the Report

This report provides quantitative assessment of the sunitinib malate market for pancreatic cancer in terms of epidemiology (incidence, 5-year survival rate), number of drug-treated patients suffering from pancreatic neuroendocrine tumor, percentage of patients eligible for taking sunitinib malate, penetration of sunitinib malate in pNET patients, pricing analysis of sunitinib malate in all G7 countries, and year-on-year market size of sunitinib malate for pancreatic cancer from 2010 to 2021.

Disease Overview

Clinical Staging

Product Profile

Sutent Market for Pancreatic Cancer

  • U.S.
  • Japan
  • Germany
  • France
  • U.K.
  • Italy
  • Spain

The sunitinib malate market for pancreatic cancer is projected to reach USD 76.7 Million by 2021, at a CAGR of 13.9% from 2016 to 2021.

This report provides quantitative assessment of the sunitinib malate market for pancreatic cancer in terms of epidemiology, number of drug-treated patients suffering from pancreatic neuroendocrine tumors (pNET), percentage of patients eligible for taking sunitinib malate, and year-on-year market size of sunitinib malate for pancreatic cancer from 2010 to 2021.

The overall sunitinib malate market for pancreatic cancer is expected to witness rapid growth owing to the increasing number of patients suffering from pancreatic cancer and growing adoption of sunitinib malate drug for pNET treatment. This report has divided the market in seven country-level segments, namely, U.S., Germany, France, U.K., Italy, Spain, and Japan. The U.S. is expected to be the largest market for sunitinib malate for pancreatic cancer, primarily due to the higher number of patients suffering from pancreatic cancer in the country. However, the market in the U.K. is expected to witness the highest growth rate during the forecast period.

Sunitinib Malate Market

This study provides an analytical framework to understand various factors that influence the growth of the sunitinib malate market for pancreatic cancer. These factors include incidence rate of pancreatic cancer, five-year survival rate of pNET patients, penetration of drug therapy for pancreatic cancer treatment, penetration of sunitinib malate in pNET patients, and trends in the adoption of sunitinib malate, among other factors. The importance of these parameters differs from country to country.

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

Table of Content

1.1 Disease Overview

1.2 Clinical Staging

1.3 Product Profile

1.4 Facts and Assumptions

1.5 Terminology

1.6 U.S.: Sutent Market for Pancreatic Cancer, 20102021

1.7 Germany: Sutent Market for Pancreatic Cancer, 20102021

1.8 France: Sutent Market for Pancreatic Cancer, 20102021

1.9 U.K.: Sutent Market for Pancreatic Cancer, 20102021

1.10 Italy: Sutent Market for Pancreatic Cancer, 20102021

1.11 Spain: Sutent Market for Pancreatic Cancer, 20102021

1.12 Japan: Sutent Market for Pancreatic Cancer, 20102021

1.13 MnM View

1.14 Sources


Request for detailed methodology, assumptions & how numbers were triangulated.

Our USP is "Customised multi client reports"-so feel free to provide us specific interest in much greater detail..!!
  • Select all
  • News-Letters with latest Market insights
  • Information & discussion on the relevant new products and services
  • Information & discussion on Market insights and Market information
  • Information & discussion on our events and conferences
    • Select all
    • Email Phone Professional and social network (Linkedin, etc)
Report Code
PH 4322
Published ON
May, 2016
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Sunitinib Malate Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
REQUEST A FREE WORKSHOP
ADJACENT MARKETS
ONLINE CHAT
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
© MarketsandMarkets Research Private Ltd. All rights reserved